HOOK · Hookipa Pharma Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.00M | - | $4.70M | $1.29M | $36.60M | - | $6.87M | $2.68M | $3.18M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $12.86M | - | $15.56M | $19.75M | $20.17M | - | $24.63M | $19.71M | $20.93M | - |
| SG&A | $6.89M | - | $6.73M | $3.94M | $4.06M | - | $4.91M | $4.45M | $4.90M | - |
| Total Operating Expenses | $19.88M | - | $23.35M | $23.75M | $25.49M | - | $29.54M | $24.15M | $25.83M | - |
| D&A | $389.0K | - | - | - | $640.0K | - | - | - | $921.0K | - |
| Operating Income | ($17.87M) | - | ($18.64M) | ($22.46M) | $11.11M | - | ($22.67M) | ($21.47M) | ($22.66M) | - |
| Interest Expense | $2.0K | - | $49.0K | $97.0K | $2.0K | - | $49.0K | $97.0K | $122.0K | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $205.0K | - |
| Net Income | ($15.43M) | - | ($13.84M) | ($19.09M) | $14.38M | - | ($19.07M) | ($18.02M) | ($19.68M) | - |
| EPS - Basic | ($1.23) | - | ($1.10) | ($1.52) | $1.10 | - | ($1.70) | ($2.20) | ($2.70) | - |
| EPS - Diluted | ($1.23) | - | ($1.10) | ($1.52) | $1.10 | - | ($1.70) | ($2.20) | ($2.70) | - |
Balance Sheet
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $40.28M | $39.68M | $59.75M | $77.15M | $92.75M | $117.10M | $107.68M | $135.59M | $109.60M | $112.49M |
| Accounts Receivable | $545.0K | $290.0K | $324.0K | $82.0K | $10.21M | $511.0K | $675.0K | $255.0K | $501.0K | $6.53M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.67M | $8.69M | $8.96M | $11.31M | $11.20M | $12.50M | $8.93M | $11.64M | $7.08M | $5.49M |
| Current Assets | $60.09M | $80.67M | $93.16M | $107.35M | $132.71M | $147.12M | $139.47M | $168.14M | $139.91M | $147.20M |
| Total Assets | $61.26M | $82.55M | $109.73M | $125.05M | $145.87M | $161.34M | $164.01M | $191.11M | $163.09M | $170.45M |
| Current Liabilities | $16.64M | $24.65M | $28.57M | $27.83M | $29.51M | $41.99M | $40.58M | $46.24M | $44.21M | $35.63M |
| Long-term Debt | - | - | - | - | $1.14M | $1.17M | $1.12M | $1.16M | $2.31M | $2.85M |
| Total Liabilities | $27.18M | $31.33M | $37.93M | $38.98M | $41.35M | $71.48M | $68.96M | $78.78M | $79.61M | $67.94M |
| Stockholders' Equity | $34.08M | $51.21M | $71.80M | $86.06M | $104.52M | $89.86M | $95.05M | $112.33M | $83.48M | $102.52M |
| Retained Earnings | ($428.19M) | ($412.76M) | ($387.81M) | ($373.97M) | ($354.88M) | ($369.26M) | ($344.44M) | ($325.38M) | ($307.36M) | ($287.68M) |
Cash Flow
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $52.0K | - | - | - | ($24.16M) | - | - | - | ($2.85M) | - |
| Investing Cash Flow | ($20.0K) | - | - | - | ($116.0K) | - | - | - | ($274.0K) | - |
| Financing Cash Flow | - | - | - | - | ($135.0K) | - | - | - | ($735.0K) | - |
| CapEx | $20.0K | - | - | - | $116.0K | - | - | - | $274.0K | - |
| Free Cash Flow | $32.0K | - | - | - | ($24.27M) | - | - | - | ($3.12M) | - |
Ratios
| Metric | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -891.9% | - | -396.4% | -1740.9% | 30.3% | - | -330.1% | -801.5% | -713.4% | - |
| EBITDA margin | -872.5% | - | - | - | 32.1% | - | - | - | -684.4% | - |
| Net margin | -769.8% | - | -294.3% | -1480.2% | 39.3% | - | -277.6% | -672.5% | -619.6% | - |
| Free cash flow margin | 1.6% | - | - | - | -66.3% | - | - | - | -98.3% | - |
| FCF / Net income | -0.00 | - | - | - | -1.69 | - | - | - | 0.16 | - |
| R&D / Revenue | 641.7% | - | 331.0% | 1530.9% | 55.1% | - | 358.6% | 735.6% | 659.0% | - |
| SG&A / Revenue | 343.6% | - | 143.1% | 305.8% | 11.1% | - | 71.5% | 165.9% | 154.3% | - |
| Effective tax rate | - | - | - | - | 0.0% | - | - | - | - | - |
| Return on assets | -25.2% | - | -12.6% | -15.3% | 9.9% | - | -11.6% | -9.4% | -12.1% | - |
| Return on equity | -45.3% | - | -19.3% | -22.2% | 13.8% | - | -20.1% | -16.0% | -23.6% | - |
| Return on invested capital | - | - | - | - | 10.5% | - | -18.6% | -14.9% | -20.9% | - |
| Liquidity | ||||||||||
| Current ratio | 3.61 | 3.27 | 3.26 | 3.86 | 4.50 | 3.50 | 3.44 | 3.64 | 3.16 | 4.13 |
| Quick ratio | 3.61 | 3.27 | 3.26 | 3.86 | 4.50 | 3.50 | 3.44 | 3.64 | 3.16 | 4.13 |
| Cash ratio | 2.42 | 1.61 | 2.09 | 2.77 | 3.14 | 2.79 | 2.65 | 2.93 | 2.48 | 3.16 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.03 |
| Debt / Assets | - | - | - | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 |
| Debt / EBITDA | - | - | - | - | 0.10 | - | - | - | - | - |
| Interest coverage | -8937.0x | - | -380.5x | -231.5x | 5553.0x | - | -462.7x | -221.4x | -185.7x | - |
| Equity multiplier | 1.80 | 1.61 | 1.53 | 1.45 | 1.40 | 1.80 | 1.73 | 1.70 | 1.95 | 1.66 |
| Liabilities / Assets | 0.44 | 0.38 | 0.35 | 0.31 | 0.28 | 0.44 | 0.42 | 0.41 | 0.49 | 0.40 |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | - | 0.04 | 0.01 | 0.25 | - | 0.04 | 0.01 | 0.02 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 99d | - | 25d | 23d | 102d | - | 36d | 35d | 58d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | 6.5x | - | - | - | - | - |
| P / B | 0.4x | - | 0.8x | 0.9x | 8.6x | - | 7.2x | 6.5x | 6.4x | - |
| P / S | 6.8x | - | 11.5x | 57.5x | 24.5x | - | 99.0x | 271.7x | 167.4x | - |
| EV / EBITDA | - | - | - | - | 68.6x | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -94.5% | - | -31.5% | -51.8% | 1052.4% | - | 207.9% | -2.4% | 119.8% | - |
| Revenue CAGR (3y) | 11.5% | - | 6.7% | -37.9% | 90.4% | - | 19.3% | -26.3% | -4.9% | - |
| Revenue CAGR (5y) | -11.5% | - | 19.9% | 14.7% | 74.9% | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | 17.8% | -4.6% | - | - | -8.0% | -16.5% | -12.5% | - |
| Net income growth (YoY) | - | - | 27.4% | -6.0% | - | - | -4.3% | -10.1% | -9.5% | - |
| EPS growth (YoY) | - | - | 35.3% | 30.9% | - | - | -580.0% | -856.5% | -575.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -677.5% | - | - | - | -3186.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -67.4% | -43.0% | -24.5% | -23.4% | 25.2% | -12.3% | -16.1% | -14.9% | -43.6% | 14.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$43.95M totalSingle Reportable Segment$43.95M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing HOOKIPA Pharma Inc. against the 5 most active filers in the same SIC group.